GlassScriptPhysician profile
Trevor Robert Allison
NPI 1437145604
$4,996.20
in general payments reported to CMS, 2019-2025
28 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $251 · 2021: $1,494 · 2022: $927 · 2023: $724 · 2024: $408 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,083.09 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,044.84 | 2021-2025 | Linzess, Ubrelvy, Vraylar |
| Pfizer INC. | $575.45 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $456.18 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $203.65 | 2020-2022 | |
| Allergan, INC. | $185.34 | 2019-2020 | |
| Glaxosmithkline, LLC. | $161.10 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $147.67 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $136.46 | 2021-2025 | Eliquis, Camzyos |
| Amgen INC. | $124.71 | 2020-2025 | Evenity |
| Preventric Diagnostics, INC. | $120.49 | 2021 | |
| Amarin Pharma, INC. | $110.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.88 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.37 | 2021 | |
| Abbott Laboratories | $61.41 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.67 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $50.56 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $48.41 | 2022 | |
| Lilly USA, LLC | $47.24 | 2021-2024 | Jardiance, Zepbound |
| Daiichi Sankyo INC. | $39.46 | 2022 | |
| Exact Sciences Corporation | $25.19 | 2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $23.87 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.96 | 2022 | |
| Ironwood Pharmaceuticals, INC | $20.39 | 2021 | |
| Corcept Therapeutics | $20.19 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $19.76 | 2025 | Gardasil 9, Vaxelis, Rotateq |
| Idorsia Pharmaceuticals US INC | $15.91 | 2025 | Tryvio |
| Organon LLC | $13.54 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.